Oximio Hungary Kft
Oximio Hungary Kft is recorded as a service provider in 4 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 4 of 4 trials · Latest update first
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Confirm Efficacy and Safety of MH002 and to Assess the Effect of Dose in Patients With Mild-to-Moderate Ulcerative Colitis Insufficiently Controlled With 5-Aminosalicylic Acid
Sponsor Microbial Resource Management Health
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (ROSELLA)
Sponsor Corcept Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
CDX0159-08: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab (CDX-0159) in Adults with Active Eosinophilic Esophagitis (The “EvolvE” Study)
Sponsor Celldex Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Double-blind, Randomized, Placebo-controlled, 4-arm Parallel-group, Multiple-Dose Study to Assess Efficacy and Safety of Medical Cannabis Aerosol via the Fixed-dose Syqe Inhaler as an Add-on Treatment of Diabetic Peripheral Neuropathic Pain
Sponsor Syqe Medical Ltd.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Oximio Hungary Kft?
The 2026-10-09 snapshot links Oximio Hungary Kft to 4 distinct CTIS trials. Recorded services include Ancillary Supplies, AxMP supply, Equipment distribution (import/export activities), Importer of Record (IoR), among 6 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Oximio Hungary Kft?
The most frequently recorded therapeutic areas are Gastroenterology, Immunology, Gynecology, Solid Tumor Oncology. Recorded phases include Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Oximio Hungary Kft conducted?
The linked trials record locations in 8 countries, including Poland, Italy, Czechia, Germany, Spain. These are trial locations, not confirmed office locations or countries where Oximio Hungary Kft delivered services.
What can this page tell me about Oximio Hungary Kft's trial experience?
Browse 4 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Oximio Hungary Kft. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Oximio Hungary Kft.